Table 6 Gene ontology enrichment for the consensus networks in human datasets
From: A common gene expression signature in Huntington’s disease patient brain regions
Module | cor | GO-term (DAVID) | Potential regulators |
|---|---|---|---|
Parkinson’s disease (PD) | |||
PDpos1 | up | IκB kinase/NFκB (3.59, 0.032) | |
PDpos2 | up | lipid synthesis (2, 0.01) | |
PDneg1 | down | synapse (5.87, 0.000) | miR16 (0.036)1 |
mitochondrion (4.6, 0.000) | ESRRA (0.001)2, SF1 (0.003)2 | ||
calmodulin binding (3.12, 0.044) | |||
Myotonic dystrophy type 1 (DM1) | |||
DM1pos1 | up | regulation of neurogenesis (1.55, 0.99) | MEF2 (0.040)2, E2F (0.040)2, NR3C1 (0.040)2, PITX2 (0.040)2, ATF6 (0.040)2, VDR (0.040)2, ATF1 (0.040)2, TP53 (0.041)2 |
DM1neg1 | down | axon (1.18, 0.98) | POU2F1 (0.011)2, POU1F1 (0.034)2, IRF2 (0.048)2 |
DM1neg2 | down | enzyme activator activity (2.52, 0.049) | |
DM1neg3 | down | synapse (2.29, 0.008) | SF1 (0.001)2, REST (0.032)2 |
Myotonic dystrophy type 2 (DM2) | |||
DM2pos1 | up | lysosome (3.03, 0.043) | |
DM2pos2 | up | regulation of transcription (1.51, 0.99) | |
DM2pos3 | up | tubulin binding (1.64, 0.52) | |
DM2pos4 | up | sarcomer (1, 1.0) | |
DM2neg1 | down | mitochondrion (3.09, 0.01) | |
DM2neg2 | down | dendrite (1.91, 0.51) | NRF1 (0.009)1, ETS1 (0.054)1 |
Ganglioglioma (GG) | |||
GGpos1 | up | inflammatory response (6.32, 0.002) | NFκB (0.022)1, miR124 (0.022)1, miR106b (0.022)1, MYOG (0.066)1 |
cell adhesion/extracellular matrix (4.13, 0.002) | ELF1 (0.000)2, IRF8 (0.008)2, MYB (0.008)2, ELK1 (0.010)2, SPI1 (0.010)2, CEBPA (0.016)2, NFAT (0.029)2, IRF1 (0.034)2, STAT5A (0.034)2, AHR (0.043)2, SOX5 (0.049)2, TP53 (0.049)2 | ||
GGneg1 | down | axon (11.88, 0.000) | REST (0.000)2, SF1 (0.000)2, TCF3 (0.000)2, ESRRA (0.000)2, MYOD (0.000)2, RFX1 (0.000)2, RORA (0.000)2, EGR1 (0.000)2, JUN (0.000)2, TCF11 (0.000)2, ATF3 (0.000)2, LEF1 (0.000)2, PAX4 (0.000)2, E4F1 (0.000)2, CREB (0.000)2, HLF (0.001)2, MAZ (0.001)2, SP1 (0.001)2, NFIL3 (0.001)2, BACH1 (0.002)2, ATF2 (0.002)2, ATF1 (0.002)2, TFAP4 (0.002)2, TCF8 (0.003)2, ZNF238 (0.004)2, NFE2 (0.005)2, HSF1 (0.006)2, MIF (0.010)2, CUTL1 (0.012)2, SREBF1 (0.016)2, NF1 (0.020)2, MEIS1 (0.020)2, HSF2 (0.021)2, NFE2L2 (0.021)2, PCAF (0.023)2, GCF1 (0.034)2, ITGAL (0.034)2, ATF4 (0.035)2, MAF (0.038)2, TAL1 (0.043)2, NR1H4 (0.044)2, GATA2 (0.044)2, SOX9 (0.046)2 |
synapse (11.64, 0.000) | |||
microtubuli based transport (5.18, 0.000) | |||
calmodulin binding (4.87, 0.000) | |||
cytoskeleton (3.63, 0.000) | |||
neuropeptide (1.96, 0.012) | |||
signaling from G-protein families (1.49, 0.025) | |||
Renal cell carcinoma (RCC) | |||
RCCpos1 | up | inflammatory response (12.47, 0.000) | NFκB (0.06)1, E2F (0.081)1 |
regulation of IκB kinase/NFκB (5.54, 0.000) | IRF8 (0.000)2, IRF1 (0.000)2, ETS2 (0.000)2, ELF1 (0.000)2, SPI1 (0.000)2, ELF2 (0.001)2, STAT1 (0.001)2, E2F (0.001)2, ETS1 (0.007)2, GABPA (0.007)2, ELK1 (0.010)2, STAT5B (0.021)2, FOXO4 (0.022)2, TP53 (0.024)2, AHR (0.025)2, ETV4 (0.026)2, STAT3 (0.032)2, SMAD1 (0.037)2, IRF7 (0.037)2, AR (0.040)2 | ||
angiogenesis (5.17, 0.004) | |||
caspase recruitment (4.8, 0.002) | |||
regulation of transcription (4.03, 0.003) | |||
regulation of apoptosis (3.09, 0.004) | |||
extracellular matrix (2.81, 0.005) | |||
chromatin (2.6, 0.023) | |||
RCCpos2 | up | semaphorin/CD100 antigen (1.45, 0.023) | |
RCCneg1 | down | mitochondrion (31.99, 0.000) | CREB (0.006)1, NRF1 (0.006)1, miR16 (0.068)1 |
protein catabolic process/proteasome (2.29, 0.037) | SF1 (0.000)2, ESRRA (0.000)2, E4F1 (0.006)2, JUN (0.030)2, ATF3 (0.030)2, NRF1 (0.047)2 | ||
synaptic vesicle (1.34, 0.029) | |||